Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg); hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; microcrystalline cellulose; medium chain triglycerides; titanium dioxide; magnesium stearate; maize starch; stearic acid; lactose monohydrate; colloidal anhydrous silica; behenoyl polyoxyglycerides; hydrogenated castor oil; iron oxide red - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; titanium dioxide; lactose monohydrate; colloidal anhydrous silica; hydrogenated castor oil; iron oxide yellow; medium chain triglycerides; magnesium stearate; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet, modified release - excipient ingredients: maize starch; lactose monohydrate; stearic acid; hypromellose; colloidal anhydrous silica; medium chain triglycerides; indigo carmine aluminium lake; titanium dioxide; behenoyl polyoxyglycerides; copovidone; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: titanium dioxide; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch; lactose monohydrate; magnesium stearate; hydrogenated castor oil; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: copovidone; colloidal anhydrous silica; lactose monohydrate; behenoyl polyoxyglycerides; titanium dioxide; hydrogenated castor oil; stearic acid; magnesium stearate; medium chain triglycerides; maize starch; microcrystalline cellulose; hypromellose; iron oxide black; colour - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 17.857 mg (equivalent: darifenacin, qty 15 mg) - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000; iron oxide yellow; iron oxide red - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 8.929 mg (equivalent: darifenacin, qty 7.5 mg) - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000 - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.